Skip to content
Research peptides

Tri-Heal Dosage: TB-500 + BPC-157 + KPV Blend Chart

Tri-Heal dosage: the 45 mg TB-500/BPC-157/KPV vial two independent sources describe, a units chart, why the three are combined, and the untested gap.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

Tri-Heal is a research-vendor name for one vial combining three unapproved research peptides used separately for tissue recovery: TB-500, BPC-157 and KPV. Two dosing sites, fetched independently, agree the vial holds TB-500 25 mg, BPC-157 10 mg and KPV 10 mg (45 mg total). They describe once-daily dosing as a small fraction of the vial - common practice, not trial-tested. No published human or animal study has tested the three together. Each peptide has its own data on its own dosage page.

  • Two independent dosing sites agree on 45 mg total: TB-500 25 mg, BPC-157 10 mg, KPV 10 mg.
  • No published human or animal study has tested the three-peptide combination together.
  • The two sources disagree on reconstitution volume and exact dose range; both are given below.
  • Each component has separate trial or animal data alone; see the individual dosage pages.

“Tri-Heal” is a research-vendor name, not a clinical term. It refers to one vial combining three unapproved research peptides that are also sold on their own: TB-500, BPC-157 and KPV. The idea is that together they cover more of the tissue-repair process than any one alone.

This page covers what independently fetched dosing sources describe for the blend, why it is combined, and what no study has tested. For each compound’s own trial and animal data, see the TB-500 dosage page, the BPC-157 dosage page and the KPV dosage page. For the two-peptide version without KPV, see the Wolverine stack.

US legal status - Research use only

None of TB-500, BPC-157 or KPV has an FDA-approved product. All three are sold as research chemicals, not legally marketed for human use.

What’s in a Tri-Heal vial

Two independently fetched dosing sites agree on the composition: Dosage Peptide’s protocol page and Peptide Database’s protocol page. Both state a single vial holding TB-500 25 mg, BPC-157 10 mg and KPV 10 mg, for 45 mg total. That is an unequal 5:2:2 ratio, not the 1:1 split used in the Wolverine (BPC-157/TB-500) blend.

A third source, a Pure Lab Peptides product page, states the same three figures. None of the three is a regulator or a lab that verified the vial’s contents. Each states what the seller or protocol page says the label reports.

Why TB-500, BPC-157 and KPV are combined

Dosage Peptide’s explainer page says each component targets a different node of tissue repair:

  • TB-500: cell migration and cytoskeletal remodeling.
  • BPC-157: angiogenesis and growth-factor signaling.
  • KPV: melanocortin-linked anti-inflammatory signaling.

It maps the three onto separate phases of wound healing (inflammation, proliferation, remodeling). That is a mechanism argument made by a vendor source, not a finding from any study of the three peptides together. For the trial and animal data behind each claim, see the TB-500, BPC-157 and KPV dosage pages.

No study has tested this combination

I could not find a published human or animal study of TB-500, BPC-157 and KPV given together, at any dose, for any indication. Dosage Peptide’s own explainer page says the same: there are no clinical trials of the combination and no published preclinical study of the specific three-peptide mixture. Every piece of evidence behind it is component-level only.

Two of the three components have been tested as a pair, without KPV:

Neither source included KPV, so neither supports a claim about the three-way combination.

Common protocol: what’s circulating, not what’s established

No dose of the combined Tri-Heal blend is established by any study or regulator. The two dosing sites agree on the vial size and differ on the reconstitution volume and daily dose. Both describe once-daily subcutaneous or intramuscular injection.

  • Dosage Peptide: add 3.0 mL of bacteriostatic water (about 15 mg/mL total). The standard dose is roughly 1.5 mg total blend once daily (0.833 mg TB-500 plus 0.333 mg each of BPC-157 and KPV), for a 4-8 week cycle. The table below shows what that comes to on a syringe.
  • Peptide Database: add 2 mL of water (about 22.5 mg/mL). The daily dose is smaller, 200-500 mcg of total blend once daily, for a shorter 4-6 week cycle.

Neither source is a clinical or regulatory reference. This page repeats their numbers only because the site’s dosing-transparency policy calls for stating what is actually circulating.

Tri-Heal (TB-500 25 mg / BPC-157 10 mg / KPV 10 mg) 45 mg vial

Water addedConcentration1 unit =200 mcg500 mcg1 mg1.5 mg2 mg
2 mL water22.5 mg/mL225 mcg1 unit2 units4.5 units6.5 units9 units
3 mL water15 mg/mL150 mcg1.5 units3.5 units6.5 units10 units13.5 units

Units on a U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. 0.2-2 mg spans the full daily range the two sources describe for total blend per dose, at the 2 mL and 3 mL reconstitutions each independently states; neither source is a clinical or regulatory source, and the units below are for the total blend, not any single component.

Side effects and risks

No published study has looked at side effects of TB-500, BPC-157 and KPV given together, at the doses or schedule the common blend protocol describes. Each component has its own safety data, at different doses:

None of that is safety data for a three-way human combination. A vial bought outside the trial system carries no verified content, purity or actual concentration for any of the three peptides.

None of TB-500, BPC-157 or KPV has FDA approval, in any form. All three are sold as research chemicals rather than legally marketed human drugs. Combining them into one vial does not change any component’s regulatory status: it is three unapproved substances in one container, not a reviewed product. Each compound’s own dosage page has the jurisdiction-specific detail: TB-500, BPC-157 and KPV.

For where research-labelled peptides are sourced, see this site’s research-access page. It sends readers to a specific research-peptide supplier and discloses that relationship on that page.

Common questions

What is Tri-Heal?

Tri-Heal is a research-vendor name for one vial combining three unapproved research peptides that are each sold separately for tissue recovery: TB-500, BPC-157 and KPV. It is a seller and forum term, not a clinical protocol, and no regulator has reviewed it as a product.

What is the usual Tri-Heal dosage?

Two dosing sites, fetched independently, describe once-daily subcutaneous or intramuscular dosing as a small fraction of the 45 mg vial. One states roughly 0.5-2 mg of total blend per day, the other 0.2-0.5 mg. Cycles run 4-8 weeks (one site says 4-6). That is common practice reported by non-clinical dosing sites, not a dose any trial has tested for this combination. See the chart below for the units.

What comes in a Tri-Heal vial?

The product most often sold under this name is a single 45 mg vial: TB-500 25 mg, BPC-157 10 mg and KPV 10 mg. Two independently fetched dosing sites and a third seller page state the same three figures.

Why are TB-500, BPC-157 and KPV combined?

Sellers say each component acts on a different step of tissue repair: TB-500 on cell migration, BPC-157 on the blood-supply side of healing, and KPV on calming inflammation. That is a mechanism argument made by vendor sources, not a finding from a study of the three together.

Has Tri-Heal been tested in a study?

No. I could not find a published human or animal study of TB-500, BPC-157 and KPV given together. BPC-157 and TB-500 do have one published animal study testing that pair alone, without KPV; the Wolverine stack page has that data.

How do I work out reconstitution and injection volume?

That depends on your specific vial, which this page cannot know. Use the dosage calculator for your own vial rather than reusing the worked example below.

What are the side effects of Tri-Heal?

No published study has looked at side effects of the three-peptide combination at any dose. Each component has its own safety data, at doses different from the common blend protocol. The individual dosage pages give what each trial reported.

References (8 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.StudyPMID 39325560
  2. 2.Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.StudyPMID 34324435
  3. 3.Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24.StudyPMID 40131143
  4. 4.Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837.StudyPMID 42542926
  5. 5.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78.StudyPMID 18061177full text
  6. 6.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother
  7. 7.Peptide Database’s protocol page- peptide-db.comother
  8. 8.Pure Lab Peptides product page- purelabpeptides.comother

Keep reading

Related guides